Exagen (NASDAQ:XGN) Issues Earnings Results

Key Points

• Exagen reported earnings of ($0.18) EPS, matching analysts' estimates, while facing a negative net margin of 27.34%.
• The company's stock has a market cap of $157.41 million and has experienced significant price fluctuations, with a 52-week low of $1.78 and a high of $7.95.
• Analysts maintain a consensus “Buy” rating for Exagen, with price targets ranging from $7.00 to $12.00 per share.

Exagen (NASDAQ:XGN - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18), Zacks reports. The business had revenue of $17.20 million for the quarter, compared to analysts' expectations of $16.25 million. Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%. Exagen updated its FY 2025 guidance to EPS.

Exagen Stock Up 2.7%

Shares of XGN stock traded up $0.23 on Friday, hitting $8.63. The stock had a trading volume of 282,684 shares, compared to its average volume of 428,131. Exagen has a 52-week low of $1.78 and a 52-week high of $9.10. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.32 and a current ratio of 4.95. The firm has a market capitalization of $189.86 million, a price-to-earnings ratio of -9.70 and a beta of 1.61. The stock's 50 day moving average is $7.19 and its 200-day moving average is $5.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Exagen stock. Acadian Asset Management LLC bought a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 6,984 shares of the company's stock, valued at approximately $25,000. 75.25% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

XGN has been the topic of several recent research reports. KeyCorp raised shares of Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price target on the stock in a report on Wednesday. UBS Group restated an "overweight" rating on shares of Exagen in a research report on Thursday, May 15th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $10.00 price objective on shares of Exagen in a report on Wednesday. Canaccord Genuity Group increased their price target on shares of Exagen from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Craig Hallum began coverage on shares of Exagen in a research report on Wednesday, July 23rd. They set a "buy" rating and a $12.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $11.25.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).